Context Therapeutics

CNTX

Market cap $74.9M

Overview Fund Activity

0.8350 USD

-0.0010

0.12%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.8599

+0.0249

2.98%

1 day

-0.12%

5 days

2.45%

1 month

22.79%

3 months

27.95%

6 months

21.01%

Year to date

-29.83%

1 year

-61.16%

5 years

-83.63%

10 years

-83.63%

About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Employees: 9

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

3% more capital invested

Capital invested by funds: $43.7M [Q1] → $45M (+$1.25M) [Q2]

3.11% less ownership

Funds ownership: 79.61% [Q1] → 76.49% (-3.11%) [Q2]

7% less funds holding

Funds holding: 42 [Q1] → 39 (-3) [Q2]

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

379% upside

Avg. target

$5.67

579% upside

High target

$9

978% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert	$9	Buy Maintained	7 Aug 2025
HC Wainwright & Co. Emily Bodnar	$4	Buy Maintained	7 Aug 2025
Piper Sandler Biren Amin	$4	Overweight Reiterated	26 Jun 2025

See Analyst Rankings

Financial journalist opinion

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences:

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. “We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, an avidity enhanced mesothelin (“MSLN”) x CD3 bispecific antibody,” said Martin Lehr, CEO of Context.

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Context Therapeutics: Undervalued Cancer Fighter

Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers targeting solid tumors and strong early-stage clinical momentum. The company is well-capitalized, with $89 million in cash and access to additional funding, supporting operations through key Phase I data milestones into 2027. CNTX trades at a deep discount to book value and is technically oversold; positive clinical data could trigger a significant re-rating and share price upside.

Context Therapeutics: Undervalued Cancer Fighter

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers.

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors (“Board”).

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 160,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, “We continue to advance our clinical pipeline and are pleased to have two product candidates now in Phase 1 clinical trials — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody.

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Context Therapeutics Announces Chief Medical Officer Transition

Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer

Context Therapeutics Announces Chief Medical Officer Transition

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “There is a high unmet need for effective treatments in mesothelin expressing cancers.

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Zacks Investment Research

Bet on These 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.

Bet on These 5 Top-Ranked Stocks With Rising P/E

See News Rankings

Charts implemented using Lightweight Charts™